4.5 Article

Association of Pregnancy With the Onset of Clinically Isolated Syndrome

Journal

JAMA NEUROLOGY
Volume 77, Issue 12, Pages 1496-1503

Publisher

AMER MEDICAL ASSOC
DOI: 10.1001/jamaneurol.2020.3324

Keywords

-

Funding

  1. MS Research Australia
  2. Australian Government Research Training Program Scholarship
  3. NHMRC [1156519]
  4. Roche
  5. Merck
  6. Biogen
  7. Novartis
  8. Bayer Schering
  9. Sanofi Genzyme
  10. Teva
  11. National Health and Medical Research Council of Australia [1156519] Funding Source: NHMRC

Ask authors/readers for more resources

Question Do pregnancies and childbirths delay the onset of clinically isolated syndrome (CIS)? Findings In this multicenter cohort study of 2557 women with CIS, women with previous pregnancies and childbirths had a later onset of CIS compared with women without pregnancies and childbirths. A higher number of pregnancies and childbirths was not associated with later CIS onset. Meaning Findings of this study suggest that future research is needed to explore the mechanisms underpinning the association between pregnancy and timing of the first presentation of multiple sclerosis. Importance Multiple sclerosis (MS) is usually diagnosed in women during their childbearing years. Currently, no consensus exists on whether pregnancy can delay the first episode of demyelination or clinically isolated syndrome (CIS). Objective To investigate the association of pregnancy with time to CIS onset. Design, Setting, and Participants This multicenter cohort study collected reproductive history (duration of each pregnancy, date of delivery, length of breastfeeding) on all participants between September 1, 2016, and June 25, 2019. Adult women being treated at the MS outpatient clinics of 4 tertiary hospitals in 2 countries (Charles University and General University Hospital in Prague, Czech Republic; Royal Melbourne Hospital in Melbourne, Australia; Alfred Hospital in Melbourne, Australia; and John Hunter Hospital in Newcastle, Australia) were recruited to participate in the study. Preexisting data (date of CIS onset, date of birth, sex, date of clinical onset, and Expanded Disability Status Scale result) were collected from MSBase, an international registry of long-term prospectively collected data on patients with MS. Data analyses were performed from June 1, 2019, to February 3, 2020. Exposures Gravida (defined as any pregnancy, including pregnancy that ended in miscarriage and induced abortion) and parity (defined as childbirth after gestational age of more than 20 weeks, including livebirth and stillbirth) before CIS onset. Main Outcomes and Measures Time to CIS onset. The following were assessed: (1) whether women with previous pregnancies and childbirths had a delayed onset of CIS compared with those who had never been pregnant and those who had never given birth, and (2) whether a dose response existed, whereby a higher number of gravidity and parity was associated with a later onset of CIS. Results Of the 2557 women included in the study, the mean (SD) age at CIS onset was 31.5 (9.7) years. Of these women, before CIS onset, 1188 (46%) had at least 1 pregnancy and 1100 (43%) had at least 1 childbirth. The mean (SD) age at first pregnancy was 23.3 (4.5) years and at first childbirth was 23.8 (4.5) years. Women with previous pregnancies and childbirths had a later onset of CIS compared with those who had never been pregnant (HR, 0.68; 95% CI, 0.62-0.75;P < .001), with a median delay of 3.3 (95% CI, 2.5-4.1) years. Women who had given birth also had a later CIS onset compared with women who had never given birth (HR 0.68; 95% CI, 0.61-0.75;P < .001), with a similar median delay of 3.4 (95% CI, 1.6-5.2) years. A higher gravidity and parity number was not associated with delay in CIS onset. Conclusions and Relevance This study suggests an association between previous pregnancies and childbirths and timing of CIS onset, but having more pregnancies or childbirths did not appear to be associated with a later CIS onset. Further studies are needed to help explain the mechanisms behind the associations between pregnancy and onset of multiple sclerosis. This cohort study examines the implications of previous pregnancy and childbirth for the timing of clinically isolated syndrome among women of childbearing age.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Clinical Neurology

Prediction of relapse activity when switching to cladribine for multiple sclerosis

Michael Zhong, Anneke van der Walt, Mastura Monif, Suzanne Hodgkinson, Sara Eichau, Tomas Kalincik, Jeannette Lechner-Scott, Katherine Buzzard, Olga Skibina, Vincent Van Pesch, Ernest Butler, Julie Prevost, Marc Girard, Jiwon Oh, Helmut Butzkueven, Vilija Jokubaitis

Summary: Relapse during or prior to the treatment gap, and younger age, were found to be prognostic factors in the year after switching to cladribine. Switching from NTZ was also independently associated with a higher risk of relapse.

MULTIPLE SCLEROSIS JOURNAL (2023)

Article Clinical Neurology

Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network

Alessio Signori, Johannes Lorscheider, Sandra Vukusic, Maria Trojano, Pietro Iaffaldano, Jan Hillert, Robert Hyde, Fabio Pellegrini, Melinda Magyari, Nils Koch-Henriksen, Per Soelberg Sorensen, Tim Spelman, Anneke van Der Walt, Dana Horakova, Eva Havrdova, Marc Girard, Sara Eichau, Francois Grand'Maison, Oliver Gerlach, Murat Terzi, Serkan Ozakbas, Olga Skibina, Vincent Van Pesch, Maria Jose Sa, Julie Prevost, Raed Alroughani, Pamela A. McCombe, Riadh Gouider, Saloua Mrabet, Tamara Castillo-Trivino, Chao Zhu, Koen de Gans, Jose Luis Sanchez-Menoyo, Bassem Yamout, Samia Khoury, Maria Pia Sormani, Tomas Kalincik, Helmut Butzkueven

Summary: This study identifies different subgroups of patients with secondary progressive multiple sclerosis (SPMS) based on their longitudinal trajectories of disability. The findings suggest that SPMS patients progress at greatly different rates and the identification of distinct trajectories can guide better patient selection in future clinical trials. Additionally, the distinct trajectories may reflect heterogeneous pathological mechanisms of progression.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2023)

Article Clinical Neurology

Not all roads lead to the immune system: the genetic basis of multiple sclerosis severity

Vilija G. Jokubaitis, Maria Pia Campagna, Omar Ibrahim, Jim Stankovich, Pavlina Kleinova, Fuencisla Matesanz, Daniel Hui, Sara Eichau, Mark Slee, Jeannette Lechner-Scott, Rodney Lea, Trevor J. Kilpatrick, Tomas Kalincik, Philip L. De Jager, Ashley Beecham, Jacob L. McCauley, Bruce Taylor, Steve Vucic, Louise Laverick, Karolina Vodehnalova, Maria-Isabel Garcia-Sanchez, Antonio Alcina, Anneke van der Walt, Eva Kubala Havrdova, Guillermo Izquierdo, Nikolaos Patsopoulos, Dana Horakova, Helmut Butzkueven

Summary: Multiple sclerosis is a leading cause of adult neurological disability, and the clinical heterogeneity of the disease has made it difficult to identify genetic variants associated with outcomes. Researchers used a large international multiple sclerosis registry and machine learning to find genetic loci associated with disease severity. They found that multiple genetic loci of small effect sizes contribute to clinical outcomes.

BRAIN (2023)

Article Biochemistry & Molecular Biology

The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study

Shobana Anpalakhan, Prerana Huddar, Roya Behrouzi, Alessio Signori, Judith Cave, Charles Comins, Alessio Cortellini, Alfredo Addeo, Carles Escriu, Hayley McKenzie, Gloria Barone, Lisa Murray, Gagan Bhatnagar, David J. Pinato, Christian Ottensmeier, Fabio Gomes, Giuseppe Luigi Banna

Summary: GCSF prophylaxis is recommended in patients on chemotherapy with a >20% risk of febrile neutropenia and is to be considered if there is an intermediate risk of 10-20%. GCSF has been suggested as a possible adjunct to immunotherapy due to increased peripheral neutrophil recruitment and PD-L1 expression on neutrophils with GCSF use and greater tumour volume decrease with higher tumour GCSF expression. However, its potential to increase neutrophil counts and, thus, NLR values, could subsequently confer poorer prognoses on patients with advanced NSCLC.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Medicine, Research & Experimental

Gene's expression underpinning the divergent predictive value of [18F]F-fluorodeoxyglucose and prostate-specific membrane antigen positron emission tomography in primary prostate cancer: a bioinformatic and experimental study

Matteo Bauckneht, Cecilia Marini, Vanessa Cossu, Cristina Campi, Mattia Riondato, Silvia Bruno, Anna Maria Orengo, Francesca Vitale, Sonia Carta, Silvia Chiola, Sabrina Chiesa, Alberto Miceli, Francesca D'Amico, Giuseppe Fornarini, Carlo Terrone, Michele Piana, Silvia Morbelli, Alessio Signori, Paola Barboro, Gianmario Sambuceti

Summary: This study investigated the independent and additive prognostic value of PSMA and FDG gene expression in risk-stratification of prostate cancer (PCa). Machine learning analysis identified a predictive functional network involving glucose metabolism-related genes. Cellular experiments showed that increased proliferation and migration of PCa cells were associated with enhanced FDG uptake and decreased PSMA retention, indicating the prognostic value of FDG PET imaging.

JOURNAL OF TRANSLATIONAL MEDICINE (2023)

Article Clinical Neurology

Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis

Giacomo Boffa, Alessio Signori, Luca Massacesi, Alice Mariottini, Elvira Sbragia, Salvatore Cottone, Maria Pia Amato, Claudio Gasperini, Lucia Moiola, Stefano Meletti, Anna Maria Repice, Vincenzo Brescia Morra, Giuseppe Salemi, Francesco Patti, Massimo Filippi, Giovanna De Luca, Giacomo Lus, Mauro Zaffaroni, Patrizia Sola, Antonella Conte, Riccardo Nistri, Umberto Aguglia, Franco Granella, Simonetta Galgani, Luisa Maria Caniatti, Alessandra Lugaresi, Silvia Romano, Pietro Iaffaldano, Eleonora Cocco, Riccardo Saccardi, Emanuele Angelucci, Maria Trojano, Giovanni Luigi Mancardi, Maria Pia Sormani, Matilde Inglese

Summary: This study compared the effects of autologous hematopoietic stem cell transplantation (AHSCT) with other anti-inflammatory disease-modifying therapies (DMTs) on long-term disability worsening in active secondary progressive multiple sclerosis (SPMS). The results showed that AHSCT was associated with a slower disability progression and a higher likelihood of disability improvement compared to standard immunotherapy.

NEUROLOGY (2023)

Article Medicine, General & Internal

External validation of unsupervised COVID-19 clinical phenotypes and their prognostic impact

Daniele Roberto Giacobbe, Emilio Di Maria, Alberto Stefano Tagliafico, Martina Bavastro, Carlo Simone Trombetta, Cristina Marelli, Gabriele Di Meco, Greta Cattardico, Sara Mora, Alessio Signori, Antonio Vena, Malgorzata Mikulska, Chiara Dentone, Bianca Bruzzone, Bianca Bignotti, Andrea Orsi, Chiara Robba, Lorenzo Ball, Iole Brunetti, Denise Battaglini, Antonio Di Biagio, Maria Pia Sormani, Paolo Pelosi, Mauro Giacomini, Giancarlo Icardi, Matteo Bassetti

Summary: This study validated the prognostic value of the FEN-COVID-19 phenotyping system in hospitalized COVID-19 patients and assessed the reproducibility of phenotypes development. The results showed that patients assigned to phenotype C had a higher mortality rate compared to phenotypes A and B.

ANNALS OF MEDICINE (2023)

Review Clinical Neurology

Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta-analysis and network meta-analysis

Francesco Sacca, Chiara Pane, Pablo Ezequiel Espinosa, Maria Pia Sormani, Alessio Signori

Summary: This study conducted a meta-analysis and network meta-analysis of randomized and placebo-controlled trials to evaluate the efficacy of innovative therapies in myasthenia gravis (MG). The results showed that anti-complement and FcRn treatments were effective in MG patients, while rituximab did not provide significant benefit.

EUROPEAN JOURNAL OF NEUROLOGY (2023)

Article Oncology

Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome?

Matilde Coriano, Diana Giannarelli, Giulia Scartabellati, Ugo De Giorgi, Nicole Brighi, Giuseppe Fornarini, Chiara Tommasi, Giulia Claire Giudice, Sara Elena Rebuzzi, Silvia Puglisi, Orazio Caffo, Stefania Kinspergher, Alessia Mennitto, Carlo Cattrini, Matteo Santoni, Elena Verzoni, Alessandro Rametta, Marco Stellato, Andrea Malgeri, Giandomenico Roviello, Matteo Brunelli, Alessio Signori, Giuseppe Luigi Banna, Sebastiano Buti

Summary: This study aimed to determine the impact of treatment modifications on the outcome of mRCC patients treated with cabozantinib or pazopanib. The results showed that treatment modifications based on toxicities were associated with longer PFS and OS, including dose reductions, temporary interruption, and schedule modifications. These findings were confirmed through multivariable and landmark analyses.

EXPERT REVIEW OF ANTICANCER THERAPY (2023)

Article Clinical Neurology

Disability accrual in primary and secondary progressive multiple sclerosis

Sam Harding-Forrester, Izanne Roos, Ai-Lan Nguyen, Charles B. Malpas, Ibrahima Diouf, Nahid Moradi, Sifat Sharmin, Guillermo Izquierdo, Sara Eichau, Francesco Patti, Dana Horakova, Eva Kubala Havrdova, Alexandre Prat, Marc Girard, Pierre Duquette, Francois Grand Maison, Marco Onofrj, Alessandra Lugaresi, Pierre Grammond, Serkan Ozakbas, Maria Pia Amato, Oliver Gerlach, Patrizia Sola, Diana Ferraro, Katherine Buzzard, Olga Skibina, Jeannette Lechner-Scott, Raed Alroughani, Cavit Boz, Vincent Van Pesch, Elisabetta Cartechini, Murat Terzi, Davide Maimone, Cristina Ramo-Tello, Bassem Yamout, Samia Joseph Khoury, Daniele La Spitaleri, Maria Jose Sa, Yolanda Blanco, Franco Granella, Mark Slee, Ernest Butler, Youssef Sidhom, Riadh Gouider, Roberto Bergamaschi, Rana Karabudak, Radek Ampapa, Jose Luis Sanchez-Menoyo, Julie Prevost, Tamara Castillo-Trivino, Pamela A. McCombe, Richard Macdonell, Guy Laureys, Liesbeth Van Hijfte, Jiwon Oh, Ayse Altintas, Koen de Gans, Recai Turkoglu, Anneke van der Walt, Helmut Butzkueven, Steve Vucic, Michael Barnett, Edgardo Cristiano, Suzanne Hodgkinson, Gerardo Iuliano, Ludwig Kappos, Jens Kuhle, Vahid Shaygannejad, Aysun Soysal, Bianca Weinstock-Guttman, Bart Van Wijmeersch, Tomas Kalincik

Summary: This study compared primary and secondary progressive multiple sclerosis (PPMS, SPMS), and found that SPMS has later onset of the progressive phase and slower disability accrual, but higher baseline disability.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2023)

Article Oncology

Parity is associated with long-term differences in DNA methylation at genes related to neural plasticity in multiple sclerosis

Maria Pia Campagna, Alexandre Xavier, Jim Stankovich, Vicki E. Maltby, Mark Slee, Wei Z. Yeh, Trevor Kilpatrick, Rodney J. Scott, Helmut Butzkueven, Jeannette Lechner-Scott, Rodney A. Lea, Vilija G. Jokubaitis

Summary: This study aimed to identify DNA methylation patterns associated with parity in women with relapse-onset multiple sclerosis (wwMS). The results showed differential methylation in whole blood and immune cell types, particularly in genes related to neural plasticity. Additionally, it was found that parous women exhibited slower biological aging compared to nulligravida women.

CLINICAL EPIGENETICS (2023)

Article Immunology

The impact of menopause on multiple sclerosis

Francesca Bridge, Helmut Butzkueven, Anneke Van der Walt, Vilija G. Jokubaitis

Summary: Menopause, which refers to the permanent cessation of ovarian function, has a significant impact on sex hormone concentrations, including estrogen, progesterone, testosterone, and anti-Mullerian hormone. These hormones are believed to have neuroinflammatory effects and are implicated in the development of multiple sclerosis (MS). Understanding the relationship between sex hormones and MS disease activity, particularly during menopause, is crucial for providing optimal care and making treatment decisions to minimize relapses, disease progression, and improve quality of life for women with MS.

AUTOIMMUNITY REVIEWS (2023)

Article Biochemistry & Molecular Biology

DNA Methylation Signatures of Multiple Sclerosis Occur Independently of Known Genetic Risk and Are Primarily Attributed to B Cells and Monocytes

Alexandre Xavier, Vicki E. Maltby, Ewoud Ewing, Maria Pia Campagna, Sean M. Burnard, Jesper N. Tegner, Mark Slee, Helmut Butzkueven, Ingrid Kockum, Lara Kular, Vilija G. Jokubaitis, Trevor Kilpatrick, Lars Alfredsson, Maja Jagodic, Anne-Louise Ponsonby, Bruce V. Taylor, Rodney J. Scott, Rodney A. Lea, Jeannette Lechner-Scott

Summary: This study reveals that DNA methylation differences in multiple sclerosis (MS) occur independently of known genetic risk loci. It shows that these differences more effectively differentiate the disease compared to known genetic risk loci. The study also indicates that the methylation differences in MS predominantly occur in B cells and monocytes, involving cell-specific biological pathways.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Clinical Neurology

Evaluation of Cell-Specific Epigenetic Age Acceleration in People With Multiple Sclerosis

Vicki Maltby, Alexandre Xavier, Ewoud Ewing, Maria-Pia Campagna, Sandeep Sampangi, Rodney J. Scott, Helmut Butzkueven, Vilija Jokubaitis, Lara Kular, Steffan Bos, Mark Slee, Ingrid A. van der Mei, Bruce V. Taylor, Anne-Louise Ponsonby, Maja Jagodic, Rodney Lea, Jeannette Lechner-Scott

Summary: This study used existing DNAm data from multiple independent studies to investigate cell-specific epigenetic age acceleration (EAA) in people with multiple sclerosis (MS). The results showed that MS patients had significantly increased EAA compared to controls, and this effect was specifically associated with B cells. This study provides evidence for the role of premature B cell immune senescence in MS.

NEUROLOGY (2023)

Review Clinical Neurology

Optimization of extraction process of Sarcandra glabra by combination of entropy weight method with Box- Behnken response surface method

Kristen M. Krysko, Ruth Dobson, Raed Alroughani, Maria Pia Amato, Riley Bove, Andrea Ciplea, Yara Fragoso, Maria Houtchens, Vilija G. Jokubaitis, Melinda Magyari, Azza Abdelnasser, Vasantha Padma, Sandra Thiel, Mar Tintore, Sandra Vukusic, Kerstin Hellwig

Summary: Multiple sclerosis (MS) is frequently diagnosed in women intending to have children. The effects of fetal exposure to novel disease-modifying therapies (DMTs) used in the treatment of MS are not well understood. Discontinuation of certain DMTs during pregnancy may increase the risk of relapse and disability. More research is needed to understand the outcomes of neonates exposed to DMTs and guide individualized treatment decisions. Periodic updates will be necessary to provide the latest guidance on achieving MS stability during pregnancy and postpartum while ensuring the safety of the mother and newborn.

LANCET NEUROLOGY (2023)

No Data Available